To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The effect of LongoVital … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial.

Journal article
Authors John Bratel
Magnus Hakeberg
Mats Jontell
Published in Oral health & preventive dentistry
Volume 3
Issue 1
Pages 3-8
ISSN 1602-1622
Publication year 2005
Published at Institute of Odontology
Pages 3-8
Language en
Keywords Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Phytotherapy, Plant Components, Plant Preparations, therapeutic use, Plants, Medicinal, Recurrence, prevention & control, Statistics, Nonparametric, Stomatitis, Aphthous, prevention & control, Tablets, Vitamins, therapeutic use
Subject categories Dentistry, Other odontology


PURPOSE: The aim of this study was to evaluate the effect of daily intake of LongoVital (LV) (herbal vitamin tablets) in the prevention of RAS. MATERIALS AND METHODS: A group of 78 consecutively referred patients was enrolled to a three-months pretreatment period. Fifty subjects were then randomly allocated to an LV-group (n = 25) or a placebo group (N = 25). A double blind, stratified-randomised clinical case-control study was performed during six months. Number and size of the ulcers were registered by the patients using a standardized chart. The degree of discomfort was recorded on a 100 mm horizontal visual analogue scale (VAS-scale). RESULTS: The three-months pretreatment period revealed that the most dominant symptoms were pain (78%) followed by burning sensation (18%). No significant differences between the two groups were found during this period when a comparison was made at the end of the study. After the intervention period the number of aphthous ulcers/month decreased significantly in the LV-group (p = 0.02). The number of days in pain/month were also reduced (p < 0.001). If a 50% reduction of number of aphthous ulcers and days in pain were considered as clinically relevant, no statistical significant differences were found between the groups. CONCLUSION: Thus, no strong evidence was found that justified a recommendation of LV as a general drug for treatment of RAS.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?